10 "Head and neck cancer" clinical trials found.
-
Phase II: Adaptive De-escalation of Radiation Therapy Dose In Favorable Risk HPV-Positive Oropharyngeal Carcinoma (ART)
The main goal of this study is to determine if deescalating chemoradiation treatment based on early tumor shrinkage at mid-treatment can result in similar cancer ...
-
Site for Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
The purpose of the study is to determine whether docetaxel alone is as active as docetaxel and cetuximab combination and whether either taxane-based regimen is ... -
RANDOMIZED PHASE II/III TRIAL OF SENTINEL LYMPH NODE BIOPSY VERSUS ELECTIVE NECK DISSECTION FOR EARLY-STAGE ORAL CAVITY CANCER
The purpose of the study is to compare Elective Neck Dissection (END) and Sentinel Lymph Node (SLN) Biopsy in terms of shoulder related-quality of life ... -
Photobiomodulation Therapy Using the MuReva Phototherapy System to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Patients with Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy
The overall purpose of this clinical study is to evaluate safety and efficacy of the MuReva Phototherapy System with a light delivery mouthpiece to reduce ... -
A Phase 2 Study of Darolutamide in Combination with Leuprolide Acetate in Hormone-Therapy Na ve Recurrent and/or Metastatic Androgen Receptor (AR) Positive Salivary Gland Cancer
We want to study if combining two drugs, ADT and darolutamide, can help patients with a type of cancer called salivary gland carcinoma. We will ...
-
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810) ADMINISTERED INTRALESIONALLY FOR PATIENTS WITH RECURRENT CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC)
The main purpose of this study is to determine the safet and tolerability of cemiplimab. Cemiplimab-rwic is only approved by the U.S. Food and ... -
A Phase I Multicenter Open-label First-in Human Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors
This study is designed for patients diagnosed with advanced solid tumors. This is a study for the first time testing of a new medicine called ...
-
A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors
If you have been diagnosed with solid tumors, either removed previously by surgery or unresectable (locally advanced or metastatic), you may qualify for this phase ... -
A first-in-human Phase I non-randomized open-label multicentre dose escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by repeated intravenous infusions in patients with malignant solid tumors expressing B7-H6
This study is testing different doses of a dtreatment called BI 765049, either alone or with another drug called ezabenlimab for patients with tumors expressing ...
-
A Phase 1/2 First-in-Human Study of DCC-3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations
This study is designed for patients who have Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway MutationsThe objective of the study is to ...